CytomX Therapeutics (CTMX) Capital Expenditures (2014 - 2025)
CytomX Therapeutics' (CTMX) quarterly Capital Expenditures came in at $201000.0 in Q4 2025, up 151.25% YoY from $80000.0 in Q4 2024, and up 258.27% on a QoQ basis from -$127000.0 in Q3 2025.
CytomX Therapeutics (CTMX) Capital Expenditures (2014 - 2025) Analysis & Trends
CytomX Therapeutics (CTMX) has 12 years of Capital Expenditures data on file, last reported at $201000.0 in Q4 2025.
- Quarterly Capital Expenditures rose 151.25% year-over-year to $201000.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $101000.0 (down 67.83% YoY) and the FY2025 annual result came in at $220000.0, down 29.03% from the prior year.
- Capital Expenditures grew to $201000.0 in Q4 2025, from -$127000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $982000.0 in Q1 2021 to a low of -$499000.0 in Q4 2023.
- A 5-year average of $197700.0 and a median of $117000.0 in 2024 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2022 — Capital Expenditures surged 261.4% — and 2025, when it tumbled 768.42%.
- Tracing CTMX's Capital Expenditures over 5 years: stood at $245000.0 in 2021, then retreated by 25.71% to $182000.0 in 2022, then plunged by 374.18% to -$499000.0 in 2023, then jumped by 116.03% to $80000.0 in 2024, then surged by 151.25% to $201000.0 in 2025.
- The last three Capital Expenditures figures came in at $201000.0 (Q4 2025), -$127000.0 (Q3 2025), and $27000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | CytomX Therapeutics | 732.14 Mn | 401.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 201,000.00 |
| Dec 31, 2025 | 201,000.00 |
| Sep 30, 2025 | -127,000.00 |
| Sep 30, 2025 | -127,000.00 |
| Jun 30, 2025 | 27,000.00 |
| Jun 30, 2025 | 27,000.00 |
| Mar 31, 2025 | 119,000.00 |
| Mar 31, 2025 | 119,000.00 |
| Dec 31, 2024 | 80,000.00 |
| Dec 31, 2024 | 80,000.00 |
| Sep 30, 2024 | 19,000.00 |
| Sep 30, 2024 | 19,000.00 |
| Jun 30, 2024 | 96,000.00 |
| Jun 30, 2024 | 96,000.00 |
| Mar 31, 2024 | 115,000.00 |
| Mar 31, 2024 | 115,000.00 |
| Dec 31, 2023 | -499,000.00 |
| Dec 31, 2023 | -499,000.00 |
| Sep 30, 2023 | 9,000.00 |
| Sep 30, 2023 | 9,000.00 |